A5057512918- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Function and Risk Factors
- Parathyroid Disorders and Treatments
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Advanced MRI Techniques and Applications
- Medical Imaging and Pathology Studies
- Cardiac Valve Diseases and Treatments
- Pulmonary Hypertension Research and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Peptidase Inhibition and Analysis
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Congenital Heart Disease Studies
- Cardiomyopathy and Myosin Studies
- Cardiovascular Disease and Adiposity
- Liver Disease Diagnosis and Treatment
- Cardiac Structural Anomalies and Repair
- Potassium and Related Disorders
- Liver Disease and Transplantation
- Eosinophilic Disorders and Syndromes
- Cardiac Fibrosis and Remodeling
- Infective Endocarditis Diagnosis and Management
- Dialysis and Renal Disease Management
Medical University of Vienna
2016-2025
University Clinic of Traumatology
2023
Harvard University
2020
Massachusetts General Hospital
2020
Otto Wagner Hospital
2016-2017
Vienna General Hospital
2017
Tafamidis treatment positively affects left ventricular (LV) structure and function improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). We aimed to investigate the relationship between response cardiac burden identified by serial quantitative 99mTc-DPD SPECT/CT. furthermore identify nuclear imaging biomarkers that could be used quantify monitor tafamidis therapy.Forty wild-type ATTR-CM who underwent scintigraphy SPECT/CT at baseline after 61 mg once daily...
Myocardial extracellular volume (ECV) accumulation is one of the key pathophysiologic features heart failure with preserved ejection fraction (HFpEF). Our aims were to (1) measure ECV by cardiac magnetic resonance T1 mapping using modified Look-Locker inversion recovery (MOLLI) sequence, (2) validate MOLLI-ECV against histology, and (3) investigate relationship between prognosis in HFpEF.One-hundred seventeen consecutive HFpEF patients underwent imaging, coronary angiography, invasive...
Abstract Aims Concomitant cardiac amyloidosis (CA) in severe aortic stenosis (AS) is difficult to recognize, since both conditions are associated with concentric left ventricular thickening. We aimed assess type, frequency, screening parameters, and prognostic implications of CA AS. Methods results A total 191 consecutive AS patients (81.2 ± 7.4 years; 50.3% female) scheduled for transcatheter valve replacement (TAVR) were prospectively enrolled. Overall, 81.7% underwent complete assessment...
Tafamidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). However, it is not yet known whether tafamidis affects cardiac deposition and structural changes the myocardium. We aimed to determine disease-modifying effects on myocardial progression identify imaging parameters that could be applied for specific therapy monitoring.ATTR-CM underwent serial magnetic resonance (CMR) using T1 mapping techniques derive extracellular volume (ECV). Patients receiving 61...
Abstract Aims The presence of pulmonary hypertension (PH) severely aggravates the clinical course heart failure with preserved ejection fraction (HFpEF). To date, neither established therapies nor vasodilators proved beneficial. This study investigated efficacy chronic treatment oral soluble guanylate cyclase stimulator riociguat in patients PH-HFpEF. Methods and Results phase IIb, randomized, double-blind, placebo-controlled, parallel-group, multicentre DYNAMIC trial assessed Patients were...
Heart failure with preserved ejection fraction (HFpEF) affects more women than men, suggesting gender to play a major role in disease evolution. However, studies investigating differences HFpEF are limited. In the present study we aimed describe well-characterized cohort. Consecutive patients underwent invasive hemodynamic assessment, cardiac magnetic resonance imaging and exercise testing. Study endpoints were: death, combined endpoint of HF hospitalization or death all-cause death. 260...
Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis was shown to slow the decline in 6-minute walking distance as compared placebo. We aimed define impact of and optimal background treatment on functional capacity determined by cardiopulmonary exercise testing (CPET). Methods: Seventy-eight consecutive were enrolled study. They underwent CPET at baseline, outcome defined death or heart failure hospitalization obtained for a time period up 30 months. Fifty-four...
Background In heart failure with preserved ejection fraction (HFpEF), echocardiographic studies suggest that global longitudinal strain (GLS) has an impact on survival. Feature-tracking cardiovascular MRI also allows for analysis; however, to the knowledge of authors, little is known about its prognostic value and whether it reflects severity diffuse fibrosis, as assessed by T1 mapping. Purpose To investigate association between myocardial at extracellular volume mapping outcome in...
The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, number patients diagnosed with has increased significantly recently due to growing awareness disease, improved diagnostic capabilities demographic trends. Specific therapies that improve patient prognosis become available for certain types amyloidosis. Thus, earliest possible referral suspicion an experienced center is crucial ensure rapid diagnosis, early initiation treatment,...
Background: Extracellular volume (ECV) by cardiovascular magnetic resonance (CMR) imaging is associated with disease burden and clinical outcomes. Recent studies in patients valvular heart (VHD) have suggested that the indexed total ECV (iECV) = ECVx(LVmass/1.05)/body surface area may supersede terms of prognostication. In this study, we aimed to compare prognostic capability conventional iECV an all-comer CMR cohort. Methods: From January 2012 2023, were measured consecutive patients....
Introduction. Several randomised double-blind placebo-controlled phase III trials (RCT) explore disease-modifying therapeutics in transthyretin amyloid cardiomyopathy (ATTR-CM). However, it is currently unclear whether patients eligible to participation the RCT are representative of real-world patients. Methods. ATTR-CM presenting a tertiary referral centre for cardiac amyloidosis at Medical University Vienna between March 2012 and May 2024 were included prospective registry. Inclusion...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been found to potential hematopoietic effects in patients with heart failure (HF). However, these benefits not studied cardiac amyloidosis (CA). CA present HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis leads lower hemoglobin hematocrit levels. We sought determine the of SGLT2i hematological parameters functional capacity (FC) patients. A prospective analysis was conducted compare who...
Previous work indicates that dilatation of the pulmonary artery (PA) itself or in relation to ascending aorta (PA:Ao ratio) predicts hypertension (PH). Whether these results also apply for heart failure with preserved ejection fraction (HFpEF) is unknown. In present study we evaluated diagnostic and prognostic power PA diameter PA:Ao ratio on top right ventricular (RV) size, function, septomarginal trabeculation (SMT) thickness by cardiovascular magnetic resonance (CMR) HFpEF.
Background Diastolic dysfunction of the left ventricle is common but frequently under-diagnosed. Particularly in advanced stages affected patients may present with significant functional tricuspid regurgitation (TR) as most prominent sign on echocardiography. The underlying ventricular pathology eventually be missed and symptoms heart failure are attributed to TR, respective therapeutic consequences. aim study was determine prevalence mechanisms TR evolution preserved ejection fraction...